Upload
others
View
3
Download
0
Embed Size (px)
Citation preview
How expert centres can contribute to real-world evaluation of drugs for rare disease
Case study – The National Alkaptonuria Centre
Professor Lakshminarayan RanganathClinical Director of the National Alkaptonuria Centre
Sir
Archibald
Garrod
1857-1936Gregor Johann
Mendel (1822 – 1884)
MALEYLACETOACETATE
HOMOGENTISATE
p-HYROXYPHENYLPYRUVATE
TYROSINE
PHENYLALANINE
FUMARYLACETOACETATE
FUMARATE ACETOACETATE
Tyrosine pathway
Homogentisate
dioxygenaseAKU
Food (Dietary protein – 80-100 g/day)
• Deficiency of HGD
• Accumulation of HGA
• Polymerisation to black pigment – ochronosis
• Autosomal recessive
• 1 in 250,000
• Slovakia, DomincanRepublic, Jordan
AKU: a Rare disease
AKU: a multisystem disease
• Dark urine
• External ochronosis
• Renal/Prostate stones
• Cardiac valve damage
• Fractures
• Ruptures
• Arthritis (Joint/Spine)
Adapted from Stanbury, Wyngaarden, & Frederichson Metabolic Basis of Inherited Disease
CONNECTIVE TISSUE MACROMOLECULES
PHYSICALBONDING CHEMICAL
BONDING
Homogentisic acid 1,2 dioxygenase (HGD) deficiencyBLOCK IN ALKAPTONURIA
DIETARY PROTEIN
MALEYLACETOACETATE
TYROSINE
HOMOGENTISIC ACID
100g of protein = 4g of Phenylalanine/3g of Tyrosine
OHHO
CH2COOH CH
2COOH
=oo=
n
2 (0)HGA
POLYPHENOLOXIDASE(CU++)
POLYMER(Ochronotic
Pigment)
CH2COOH
=oo=
BENZOQUINONE ACETIC ACID
(0)HGA
POLYPHENOLOXIDASE(CU++)
Ochronosis
Lack of disease modifying therapies for AKU
Nitisinone: Action
MALEYLACETOACETATE
HOMOGENTISATE
p-HYROXYPHENYLPYRUVATE
TYROSINE
PHENYLALANINE
FUMARYLACETOACETATE
FUMARATE ACETOACETATE
Homogentisate
dioxygenaseAKU
4-hydroxyphenylpyruvate
dioxygenaseNitisinone
Funarylacetoacetate
hydrolaseHT-1
Nitisinone: Use in AKU
• Lindstedt pioneered use of nitisinone in HT 1
• Inhibits phydroxyphenylpyruvatedioxygenase
Nitisinone
Leptospermone
The Robert Gregory National
Alkaptonuria Centre (Jan 2013)April 2012
NHS England
designated
Royal Liverpool
University Hospital
to be the National
centre for AKU
National Alkaptonuria Centre (NAC)
One-Stop annual service model
Monthly clinics
Large MDT
Baseline visits: 4 days
FU annual visits: 3 days
UK Dept of Health funded
Freely available nitisinone
ITT Long term study model
Clarify Natural History
Efficacy and Safety
Developing nitisinone for AKU
• License nitisinone for AKU• Clinical trials• FP7
• Off-label use• Centre• NHS Highly
Specialised Services
• Raised HGA in AKU
• Dose of HGA determines amount of
ochronosis
• Nitisinone decreases HGA
• Nitisinone in mice prevents ochronosis if
started early
• Nitisinone in mice arrests progression of
ochronosis if started later
2013-1415
Plan of NAC Service
2012
NAC (5 years)2012-20171 - 6 visits so farNitisinone
2012-1322
2014-156
Pre NACMean FU:
36.3 months(2009-2011)
One visit onlyAssessment
No Nitisinone
2009-1117 = 12
2015-167
2016-177
Annual review model: Using Nitisinone carefully in the NAC
• Baseline: 24h urine; 2 fasting blood tests (pre- and post nitisinone)
• 2 mg alternate days for 3 months (blood/24h urine test)
• From 3 months onwards 2 mg daily (6 months: blood/24h urine test)
• Efficacy Metabolic; Clinical
• Safety Metabolic; Ocular; Skin; LFT/eGFR
n = 11 n = 11 n = 11 n = 11 n = 11 n = 11 n = 11
V4 V3 V2 V1
V0
V0
SAME GROUP
VAR GROUP
V4 V3 V2 V1
PRE-NITISINONE POST-NITISINONE
Mean age 47.7±4.4 years
n = 20 n = 47 n = 40 n = 36 n = 34 n = 22 n = 14Mean 47.8±3.1 47.3±2.3 48.3±2.3 48.7±2.6 47.3±3.4 47.3±3.4 47.3±3.4Age years
V5 V6
V5 V6
Cumulative safety54 received nitisinone 2mg (4 self-paid)
• 4 deceased
• 4 on hold
• 1 intermittent dose
Adverse Effects reported:
Haematuria (2); Itch (2);
Rash (2); Odour (1);
Eye keratopathy* (5: 3 due to tyrosine);
Conjunctival injection (2); Thyroid excess (1);
GI bleed (2); Memory (2);
Abnormal LFT (1); ?Dermatomyositis (1);
Acute Haemolysis on ARF (1)
1a 1b
1c1d
MALEYLACETOACETATE
HOMOGENTISATE
p-HYROXYPHENYLPYRUVATE
TYROSINE
PHENYLALANINE
FUMARYLACETOACETATE
FUMARATE ACETOACETATE
Nitisinone
Aim of
Service Evaluation
Is there alteration in metabolicoutcomes in AKU post-nitisinone?
Nitisinone 2 mg daily oral used off-label
0
10000
20000
30000
40000
50000
60000
Baseline D4 3M 6M V2 V3 V4 V5 V6
uHGA24 umol/day
Urine HGA
0
10
20
30
40
50
60
70
80
90
Baseline D4 3M 6M V2 V3 V4 V5 V6
sHGA umol/L
Serum HGA
95%↓ in NAC
0
200
400
600
800
1000
1200
1400
Baseline D4 3M 6M V2 V3 V4 V5 V6
sTYR umol/L
>10 fold increase in NAC
Serum Tyrosine
Effects of AKU
The NAC GroupIs there alteration in NON-metabolic outcomes in
AKU post-nitisinone?Nitisinone 2 mg daily oral used off-label
Alkaptonuria Severity Score Index (AKUSSI)
AKUSSICLINICAL
JOINTSPINE
ALL
FEATURE TEST FEATURE TEST
Eye Pigment R Eye Nasal PHOTO L Eye Nasal PHOTO
R Eye Temporal PHOTO L EyeTemporal PHOTO
Ear Pigment RIGHT ear PHOTO LEFT ear PHOTO
OCHRONOSIS
Mild (1) Mod (2) Marked (3)
SUPERFICIAL CONJUNCTIVAL PIGMENTATION
Eye scoring
DEEPER SCLERAL PIGMENTATION
Mild (4) Mod (6) Marked (8)
Present (2) Marked (4)
Ear scoring
Data shown
For 2 groups of data
N = 11 – same 11 patients in all visits
N = variable – variable numbers of pairs of data at different visits
Ochronosis data (eye+ear)
ALL AKUSSI data (CLIN+JOINT+SPINE)
ACTUAL SCORES AS BOXPLOTS
RATE OF CHANGE/PATIENT/MONTH AS BOXPLOTS
75th centileMean
Median
90th centile
25th centile
10th centile
B
BB
B B BB
Pre Base Y1 Y2 Y3 Y4 Y5
-5
5
15
25
35
OchronosisSCORES
GROUPN = 11
P<0.002 p<0.06
p<0.004
Base – Pre score
Base - Pre time months
15 - 8
39 months
0.18/month
5y - Base score
5y - Base time
13 - 15
60 months-0.03
Ochronosis ScoresChange per patient per
monthN = 11
B
B B
BB B
P/B B/Y1 B/Y2 B/Y3 B/Y4 B/Y5
-0.25
-0.2
-0.15
-0.1
-0.05
0
0.05
0.1
0.15
ALL AKUSSI
Summary of Features
Total 55 (Engl/Scot) 23 Female 52.3+15.8 yrs 32 Male 48.5+14.9 yrs
Asian 17 (Engl/Scot) 6 Female 38.5+13.4 yrs 14 Male 48.4+13.9yrs
Prostate stones 27 (72) 37.5%
Renal stones 22 (ep) 26.4%
Osteopenia 48 (72) 66.7%
Aortic valve disease (Scl/Mild/Mod/Severe) 26/10/2/4 58.3%
Fractures 46 (72)
Ruptures (ligament,tendon,muscle) 45 (72)
Joint replacements (in 26 patients) 92 (72)
FEATURE TEST FEATURE TEST
Eye Pigment R Eye Nasal PHOTO L Eye Nasal PHOTO
R Eye Temporal PHOT L EyeTemporal PHOTO
Ear Pigment RIGHT ear PHOTO LEFT ear PHOTO
Prostate Stones (4 per
episode)
US/HIS
T
Kidney Stones (4 per
episode)
US/HIST
Osteopenia (4) CT-
BMD
Hearing impairment
(4)
HIST
Aortic sclerosis (6), Aortic stenosis (mild, moderate,
severe) (8,10,12)
ECHO
Fracture (8 per #) HISTO
RY
Muscle rupture (8
per rupture)
HISTORY
Ligament rupture (8 per
rupture)
HISTO
RY
Tendon rupture (8
per rupture)
HISTOR
Y
CLINICAL AKUSSI
JOINT AKUSSI TEST
JOINT PAIN score (1 for each large joint area; 14
large joint areas)
HISTORY
Scintigraphic scan joint score (2 for each large
joint; 14 large joints areas)
PET
Number of joint replacements Each joint 4 HISTORY
SPINE AKUSSI TEST
SPINAL PAIN score (2 each for cervical,
thoracic, lumbar, sacroiliac)
HISTORY
Scintigraphic scan spine score (6 areas; 4
point for each area; pubic symphysis,
costochondral, Lumbar, Thoracic, Cervical,
Sacroiliac)
PET
ALL AKUSSI
B
B B B B B B
Pre Base Y 1 Y 2 Y 3 Y 4 Y 5
0
20
40
60
80
100
120
140
160
180
ALLAKUSSI SCORES
GROUPN = 11
P<0.002
ALL AKUSSISCORES
Change per patient per
monthN = 11
B
B
B B BB
P/B B/Y1 B/Y2 B/Y3 B/Y4 B/Y5
-0.4
-0.2
0
0.2
0.4
0.6
0.8
1
1.2
1.4
Echocardiographic findings
• Left ventricular systolic function was normal, except in the single patient with frequent RVOT VEs
• No significant mitral valve disease was seen
• No aortic root dilatation was seen
• Calcific aortic valve disease was common, despite absence of previous history of VHD
Aortic sclerosis 13 patients (35%)
Definite aortic stenosis 9 patients (24%)
Moderate aortic regurgitation 2 patient
Pettit SJ, Fisher M, Gallagher JA, Ranganath LR
J Inherit Metab Dis. 2011;34:1177-81.
Helliwell TR, Gallagher JA, Ranganath L.
Histopathology. 2008;53:503-12.
Progression of aortic valve disease
Pettit SJ, Fisher M,
Gallagher JA,
Ranganath LR
J Inherit Metab Dis.
2011;34:1177-81.
Correlation between Age and Peak Aortic Velocity (Orginal Cohort)
R2 = 0.62
Current Cohort (Nov 2017)
• Patients with at least 2 evaluable echocardiograms – N = 44
• Peak aortic velocity used as a measure of degree of stenosis
• Progression index calculated according to the formula:
(AoVmax2 – AoVmax1/Days)*100
Progression vs. Regression
REGRESSED Progressed
On 13 25
Not 1 5
Chi Square p = 0.39
Degree of Progression
On Nitisinone – 0.66 (3.64)
Off Nitisinone – 4.51 (3.39)
T-test – p = 0.038
What is Clinical Gait Analysis?
• 60 patients tested since 2013
• 12 are on their 5th repeated GA visit
• Detailed analysis of each individual’s gait
• Focus on cause-effect mechanisms
• Temporal and spatial charts
• Movement Deviation Profile (Barton et al 2015) – REF 2014: 4* Rating
• Detailed summary – GPs/local physiotherapist
2017 Progress Update
0
1
2
3
4
0
1
2
3
4
10 20 30 40 50 60 70 80
MD
Pm
ean
Age (years)
Deviation of AKU gait from normality (Barton et al., 2015)
Controls mean Controls
Controls mean ±SD AKU population
Your results (3 walks)
Conclusion (1)• Use of unlicensed nitisinone well tolerated and safe
• Data suggests ochronosis is slowed if not partially reversed
• Experience suggests clinical outcomes (AKUSSI, all components) are slower in terms of progression after nitisinone
• Aortic stenosis appears to progress slower after nitisinone
• Gait appears to be altered early despite minimal external ochronosis – may indicate ochronosis proceeding at the different rate in loaded osteoarticular tissue
Conclusion (2)
• Insights gained in AKU is also informing of osteoarthritis
• Knowledge of natural history and modification by therapy in younger patients requires a specialised centre approach where long term follow up is possible
USA:
Portland: M Grompe, Ms N Paulk
NIH : W Wintrone, W Gahl
Spain:
Dr Fernandez-Canon (Leon)
Italy:
Annalisa Santucci, L Tinti
Poland: Histology
UK:(Clinical)
Royal Liverpool University Hospital:
Clin Chem:L Ranganath, A Milan, A Hughes, A
Davison, J Devine, J Usher,
NAC Coordination: H Washington, P Drane
Orthopaedics: J Davidson
Rhuematology:A Daroszewska
Cardiology: M Fisher
ENT: M McCormick
Ophthalmology: M Briggs
Radiology: A Dunn
Phyiotherapy: S Taylor, N Loftus
Dietetics: S Judd
Pain relief management: A Jones
Dermatology: L West, G Sharpe
Medical Photography: J Soden
Clinical Gait Analysis: GJ Barton, H Shepherd,
S King
Nuclear Medicine: S Vinjamuri
Nurses: E Luangrath, H Bygott, G Bretland
Patients (and surgeons) providing surgical
samples
Mrs B from Sleaford and other patients
R Gregory N Sireau, Lord Ward-Atherton
Sponsors:
NHS England Highly Specialised Services
European Union
National Lottery UK
University of Liverpool
Royal Liverpool University Hospital
Swedish Orphan
Research team in University of Liverpool:
L Ranganath,
JA Gallagher,
G Bou-Gharios,
J Jarvis,
E Lock,
H Sutherland,
P Wilson,
C Keenan,
J Dillon,
L Taylor,
B Norman,
J Hughes,
M Khedr
AM Taylor
Acknowledgements
AKU Society of the UK
N Sireau
OG Timmis
L Harrison,
C Scott
R Munro
E Whitley
S Roberts
L Powell
Y Ayoob
Thank you for your attention